T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs
JA Smith, JA Bluestone - Current opinion in immunology, 1997 - Elsevier
JA Smith, JA Bluestone
Current opinion in immunology, 1997•ElsevierFc receptor nonbinding anti-CD3 monoclonal antibodies show promise for clinical
application, in that they suppress graft rejection without the toxicity associated with
conventional anti-CD3 antibody therapy. Recent studies suggest that the mechanism of
soluble anti-CD3 antibody mediated immunosuppression involves partial signaling, induced
cytokine deviation and Th1 cell inactivation.
application, in that they suppress graft rejection without the toxicity associated with
conventional anti-CD3 antibody therapy. Recent studies suggest that the mechanism of
soluble anti-CD3 antibody mediated immunosuppression involves partial signaling, induced
cytokine deviation and Th1 cell inactivation.
Fc receptor nonbinding anti-CD3 monoclonal antibodies show promise for clinical application, in that they suppress graft rejection without the toxicity associated with conventional anti-CD3 antibody therapy. Recent studies suggest that the mechanism of soluble anti-CD3 antibody mediated immunosuppression involves partial signaling, induced cytokine deviation and Th1 cell inactivation.
Elsevier
